#AIM IMMUNOTECH TRIAL#
This new potential treatment approach builds on the strong existing data demonstrating Ampligen’s broad antiviral activity against a range of respiratory viruses, and compliments the results of the recently completed Phase I clinical trial to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy. The company executive went on to note that Ampligen could be used when vaccines are not available, or where no vaccine has been developed, as the therapy uses, “the power of the virus against the virus.”Įquels added: “From a public health perspective, this may be a critical new concept, especially for future novel viral outbreaks where no vaccine has been developed.” “We have designed upcoming clinical trials with exploratory endpoints that we believe will provide data supporting this novel concept and further validate Ampligen’s potential as an early-onset intranasal therapy,” CEO Thomas K. These trials are expected to include intranasal therapeutic effect as a primary endpoint, but also exploratory endpoints to gather data supporting the Ampligen-enhanced immunity. “AIM believes that Ampligen – which is thought to be a powerful immune system modulator – can help the body respond to such an infection by first activating the innate immune system to blunt viral replication, and then, as a second important step, inducing an enhanced cross-protective immune response or a broad-based immune response, both to the virus and potential variants of the virus,” said the company.Īdditionally, the company plans to file applications for clinical trial authorization in the near future. READ: AIM ImmunoTech advances bid to study Ampligen as therapy for Post-COVID-19 Cognitive Dysfunction This therapeutic use is designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2, which causes the coronavirus (COVID-19).Īccording to AIM, the new filing concerns the early-stage administration of Ampligen following active viral replication after a respiratory virus has entered a person’s nasal passages. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.ĪIM ImmunoTech Inc ( NYSE:AIM) said it has submitted a provisional patent application for Ampligen as a potential early-onset intranasal therapy.
#AIM IMMUNOTECH SOFTWARE#
Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows.
Our human content creators are equipped with many decades of valuable expertise and experience. Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. Originally from Calgary, she has called Toronto home for more than two decades. A graduate from the University of Toronto, Georgia holds an Honours BA in Journalism. Versed in the mining space, she has spent several years covering precious metals, energy and minor metals. Georgia is a financial journalist with expertise covering the North American resource sector.
0 kommentar(er)
